SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Jan 27, 2014

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Jan. 27, 2014 · CIK: 0000921114 · Accession: 0001144204-14-004131

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 000-23930

Referenced dates: January 13, 2014

Date

January 27, 2014

Author

/s/ Stephen Thau

Form

CORRESP

Company

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)

Letter

Securities and Exchange Commission Division of Corporation Finance Re: AmpliPhi Biosciences Corporation Registration Statement on Form 10-12G Filed December 16, 2013 File No. 000-23930

Dear Ms Reischauer:

On behalf of AmpliPhi Biosciences Corporation (the “Company”), the Company hereby requests an additional five (5) business days (until February 4, 2014) to respond to the comments to the Company’s Form 10-12G contained in the Staff’s letter dated January 13, 2014.

Thank you for your assistance regarding this matter. If you have any questions please contact me at (202) 887-1571 or by email at sthau@mofo.com.

Sincerely,
/s/ Stephen Thau

Show Raw Text

CORRESP
1
filename1.htm

        2000 Pennsylvania Ave., NW

        Washington, D.C.

        20006-1888

        Telephone: 202.887.1500

        Facsimile: 202.887.0763

        www.mofo.com

        morrison &
        foerster llp

        new york, san francisco,

        los angeles, palo alto,

        sacramento, san diego,

        denver, northern virginia,

        washington, d.c.

        tokyo, london, berlin, brussels,

        beijing, shanghai, hong kong,

        singapore

January 27, 2014

BY EDGAR

Amy Reischauer

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

    Re:
    AmpliPhi Biosciences Corporation

    Registration Statement on Form 10-12G

    Filed December 16, 2013

    File No. 000-23930

Dear Ms Reischauer:

On behalf of AmpliPhi Biosciences Corporation (the “Company”),
the Company hereby requests an additional five (5) business days (until February 4, 2014) to respond to the comments to the Company’s
Form 10-12G contained in the Staff’s letter dated January 13, 2014.

Thank you for your assistance regarding this matter. If you
have any questions please contact me at (202) 887-1571 or by email at sthau@mofo.com.

Sincerely,

/s/ Stephen Thau

Stephen Thau

 cc: Philip J. Young, AmpliPhi Biosciences Corporation

SecProbe.io